As pharmaceutical giant Eli Lilly (LLY) plans to report third-quarter earnings Wednesday morning, analysts are focused on the production and sales of Mounjaro and Zepbound—two popular weight-loss drugs that have boosted the company's results.

Analysts polled by Visible Alpha expect a 28% year-over-year revenue jump to $12.2 billion. Eli Lilly is projected to swing to $1.7 billion in 澳洲幸运5开奖号码历史查询:net income from a $57.4 million net loss last year, when it reported a charge of nearly $3 billion related to "in progress 澳洲幸运5开奖号码历史查询:research and development" (IPR&D) as it closed a number of acquisitions.

Key Metric: Research and Development Costs, G🍸uidance

Ahead of Wednesday's earnings announcement, Eli Lilly said it expects to report an IPR&D charge of about $2.83 billion for the quarter, well above the $154 million and $111 million, respectively, the company reported for the first two quarters of the year.

In 澳洲幸运5开奖号码历史查询:each of its first two quarters this year, Eli Lilly lifted its 澳洲幸运5开奖号码历史查询:full-year outlook on the strength of sales for its weight loss drܫugs.

Deutsche Bank analysts wrote last week that they believe the drugmaker will affirm its outlook rather than raise it again. The analysts cited a shifting production environment for Eli Lilly's weight loss drugs, and said sales may have slowed in parts of the U.S. because of the impact of Hurricane Helene on some pharmacies in the Southeast U.S in the quarter.

Business Spotlight: Mounjaro, Zepbound No Longeꩲr in Shortag꧋e

The company's weight loss drugs were dropped from the 澳洲幸运5开奖号码历史查✤询:Food and Drug Administration's (FDA) 澳洲幸运5开奖号码历史查询:shortage list during the quarter, as the agency currently notes the shortage of Mounjaro and Zepbound's 澳洲幸运5开奖号码历史查询:active ingredient tirzepatide as "resolved."

Both Eli Lilly and Danish drugmaker Novo Nordisk (NVO) have 澳洲幸运5开奖号码历史查询:seen their sales surge over the last several quarters as demand has spiked for their weight loss drugs, with each company 澳洲幸运5开奖号码历史查询:spending billions to 澳洲幸运5开奖号码历史查询:increase production to meet demand.

Eli Lilly said in its 澳洲幸运5开奖号码历史查询:second quarter earnings call that its supply of the drugs should improve through the back half of 2024, but said it could still face "periodic supply tightness" as demand remained high. The company 澳洲幸运5开奖号码历史查询:also launched a lower-cost and easier-to-produce🌜 version of Zepbound🐟 in the quarter.

Eli Lilly shares edged higher Monday, finishing just under $896. The stock is up more than 50% this year.